NICE technology appraisal guidance
Issued: October 2004
TA86
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta86
Important information about this guidance
November 2010: This guidance has been partially updated by 'Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours' (NICE technology appraisal guidance 209).